

Neuland Laboratories Limited Sanali Info Park, 'A' Block, Ground Floor, 8-2-120/113 Road No. 2, Banjara Hills Hyderabad - 500 034. Telangana, India.

Tel: 040 30211600 / 23551081 Fax: 040 30211602 Email: neuland@neulandlabs.com www.neulandlabs.com

May 18, 2020

To BSE Limited Phiroze Jeejeebhoy Towers, 25th Floor, Dalal Street, Mumbai - 400 001 To
The National Stock Exchange of India Ltd
Exchange Plaza,
Bandra Kurla Complex
Bandra (E), Mumbai - 400 001

Scrip Code: 524558

Scrip Code: NEULANDLAB; Series: EQ

Dear Sirs,

Results Release and Earnings Call Notice

We refer to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), 2015 and enclose a copy of the Q4 FY 2019-2020 Earnings Call details, for your information and records.

Thanking you,

Yours faithfully,

For Neuland Laboratories Limited

Sarada Bhamidipati Company Secretary

M No: 27854

Encl: As above



Neuland Laboratories Limited's Q4 & Full Year 2019-20 Results Conference Call At 16:00 hrs. IST on May 22, 2020

Neuland Laboratories Limited will announce its results for the fourth quarter ended March 31, 2020 on May 22, 2020. The results will also be made available on the website of the Company, www.neulandlabs.com.

Following the announcement, the management of the Company will host an Earnings Call on the 22 May at 16:00 hrs. The details of the earnings call are:

Date: May 22, 2020

Time: 16:00 Hrs.

Dial-in Number: +91 22 6280 1107 / +91 22 7115 8008

Other Numbers:

Local Access Number

+91 70456 71221 (Available all over India)

International Toll-Free Number

USA - 18667462133 | UK - 08081011573 | Singapore - 8001012045 | Hong Kong - 800964448

About Neuland Laboratories Limited (BSE:524558, NSE: NEULANDLAB)

For over 35 years, Neuland Labs has been at the forefront of manufacturing APIs through its cGMP manufacturing facilities, working with customers in close to 80 countries. Neuland Labs has developed more than 300 processes and 75 APIs, and has filed over 876 Regulatory filings in the US (55 active US DMFs), the European Union (EU) and other geographies. Its manufacturing facilities are inspected and approved by the U.S. FDA and other leading regulatory agencies. Its record of quality manufacturing and reliability is highlighted by cGMP certifications that include the U.S. FDA, TGA (Australia), EDQM (EU), German Health Authority, ANVISA (Brazil), EMA (EU), Cofepris (Mexico), KFDA (Korea), PMDA (Japan), CFDA (China), FSI "SID &GP" Russia, Health Canada, ISO 9001, ISO14001, OHSAS18001 and ISO 27001.

For more information, visit www.NeulandLabs.com.

For Oueries:

Neuland: <u>ir@neulandlabs.com</u> or Diwakar Pingle: <u>dpingle@christensenir.com</u>